Novo Nordisk | NVO - Selling And Administration Expenses


Novo Nordisk reported DKK2.86B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.





Selling And Administration Expenses Change Date
ANI Pharmaceuticals USD 82.79M 6.13M Dec/2025
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Bausch Health Companies USD 801M 6M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Canopy Growth CAD 28.9M 636K Dec/2025
Corcept Therapeutics USD 114.74M 7.77M Dec/2025
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Merck USD 2.85B 215M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Novo Nordisk DKK 17.44B 1.41B Dec/2025
Novo Nordisk DKK 2.86B 13.25B Jun/2025
Pacira USD 91.87M 70K Dec/2025
Perrigo USD 255.9M 10.2M Dec/2025
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 29.67M 1.64M Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Supernus Pharmaceuticals USD 122.39M 57.29M Dec/2025
Zoetis USD 619M 40M Dec/2025